ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, today announces audited preliminary results for the year ended 31 December 2020. · Full De Novo Submission made in September 2020 for US Food and Drug Administration (FDA) clearance of the Parsortix
® system for capturing and harvesting circulating tumour cells from metastatic breast cancer patients - FDA Administrative Review complete and Substantive Review in progress - FDA Additional Information Request (AIR) received and response planned for submission in May 2021
- patient enrolment completed after the year end - surgical procedures in progress and sample analysis in preparation - study expected to report headline results in Q4 2021
Lutris Pharma Phase 1 Results of LUT014 for Skin Toxicities Associated with Treatment of Colorectal Cancer Patients with EGFR Inhibitors Published in Cancer Discovery
USA - English
LUT014 was found to be safe and effective
LUT014 Phase 2 trial designed to include 117 patients in 20 centers in the US and Israel has been initiated
News provided by
Share this article
Share this article
TEL AVIV, Israel, April 28, 2021 /PRNewswire/ Lutris Pharma, a clinical stage biopharmaceutical company focusing on improving anti-cancer therapies by reducing dose limiting side effects, announced today that results of a Phase1 study for its lead product, LUT014, assessing the safety, tolerability, and efficacy of topically administered LUT014 for the treatment of epidermal growth factor receptor (EGFR) inhibitor-induced acneiform lesions in metastatic colorectal cancer patients, were published in
Study highlights Evolutionary Aspect of Tumour Development labmate-online.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from labmate-online.com Daily Mail and Mail on Sunday newspapers.
(1)
New data with additional patients and further follow up from Study 1100, evaluating lead product candidate NBTXR3 in combination with anti-PD-1 in head and neck cancer, lung metastasis and/or liver metastasis
New data with additional patients and further follow up on safety and response rate from Study 102 dose expansion, evaluating NBTXR3 as a single agent activated by radiotherapy in head and neck cancer
Long term safety data from complete European phase II/III registration study, Act.In.Sarc, evaluating NBTXR3 as a single agent activated by radiotherapy in soft tissue sarcoma From bench-to-bedside compilation data encompassing the journey of NBTXR3 from preclinical investigation to clinical evaluation of NBTXR3 as a potentially tumor-agnostic radioenhancer that could prime adaptive immune response for both local and systemic control
Share:
WPD Pharmaceuticals Inc. (CSE:WBIO)(FSE: 8SV1) (the
Company or
WPD ) a clinical-stage pharmaceutical company, is pleased to announce that it will attend the 10
th Annual Congress of the Polish Society of Pediatric Oncology and Hematology to be held on May 6-8, 2021.
During the Congress, WPD will present the key assumptions of the WPD-201P Clinical Trial Protocol, which is planned to start in Q2 2021, as a part of the research project: New approach to glioblastoma treatment addressing the critical unmet medical need , granted by National Research and Development Center (
NRDC ) and co-financed by the European Union, under the Smart Growth Operational Program 2014-2020.